386 related articles for article (PubMed ID: 34337046)
21. Immune-Related Four-lncRNA Signature for Patients with Cervical Cancer.
Zheng J; Cao B; Zhang X; Niu Z; Tong J
Biomed Res Int; 2020; 2020():3641231. PubMed ID: 33274204
[TBL] [Abstract][Full Text] [Related]
22. A methylomics-associated nomogram predicts recurrence-free survival of thyroid papillary carcinoma.
Chen H; Ma X; Yang M; Wang M; Li L; Huang T
Cancer Med; 2020 Oct; 9(19):7183-7193. PubMed ID: 32783399
[TBL] [Abstract][Full Text] [Related]
23. Predicting biochemical-recurrence-free survival using a three-metabolic-gene risk score model in prostate cancer patients.
Zhao Y; Tao Z; Li L; Zheng J; Chen X
BMC Cancer; 2022 Mar; 22(1):239. PubMed ID: 35246070
[TBL] [Abstract][Full Text] [Related]
24. A 6 transcription factors-associated nomogram predicts the recurrence-free survival of thyroid papillary carcinoma.
Wang T; Tian K; Ji X; Song F
Medicine (Baltimore); 2021 Oct; 100(40):e27308. PubMed ID: 34622829
[TBL] [Abstract][Full Text] [Related]
25. A Metabolic-associated Nomogram Predicts Recurrence Survival of Thyroid Cancer.
Xi ZH; Ma XX; Chen HY; Yu YH; Li L; Huang T
Curr Med Sci; 2021 Oct; 41(5):1004-1011. PubMed ID: 34510328
[TBL] [Abstract][Full Text] [Related]
26. A Comprehensive Prognostic and Immunological Analysis of a Six-Gene Signature Associated With Glycolysis and Immune Response in Uveal Melanoma.
Liu J; Lu J; Li W
Front Immunol; 2021; 12():738068. PubMed ID: 34630418
[TBL] [Abstract][Full Text] [Related]
27. A Novel Prognostic Risk Model for Cervical Cancer Based on Immune Checkpoint HLA-G-Driven Differentially Expressed Genes.
Xu HH; Wang HL; Xing TJ; Wang XQ
Front Immunol; 2022; 13():851622. PubMed ID: 35924232
[TBL] [Abstract][Full Text] [Related]
28. Construction and validation of an autophagy-related long noncoding RNA signature for prognosis prediction in kidney renal clear cell carcinoma patients.
Yu J; Mao W; Xu B; Chen M
Cancer Med; 2021 Apr; 10(7):2359-2369. PubMed ID: 33650306
[TBL] [Abstract][Full Text] [Related]
29. Recurrence-associated gene signature optimizes recurrence-free survival prediction of colorectal cancer.
Tian X; Zhu X; Yan T; Yu C; Shen C; Hu Y; Hong J; Chen H; Fang JY
Mol Oncol; 2017 Nov; 11(11):1544-1560. PubMed ID: 28796930
[TBL] [Abstract][Full Text] [Related]
30. Development and Validation of a Nomogram-Based Prognostic Evaluation Model for Sarcomatoid Hepatocellular Carcinoma.
Ge D; Luo Z; Mao R; Zhao H; Lv X; Zhao J; Zhou J; Huang Z; Zhang Y; Li Z; Bi X; Cai J
Adv Ther; 2020 Jul; 37(7):3185-3205. PubMed ID: 32436026
[TBL] [Abstract][Full Text] [Related]
31. Identification and validation of a potent multi-mRNA signature for the prediction of early relapse in hepatocellular carcinoma.
Cai J; Tong Y; Huang L; Xia L; Guo H; Wu H; Kong X; Xia Q
Carcinogenesis; 2019 Jul; 40(7):840-852. PubMed ID: 31059567
[TBL] [Abstract][Full Text] [Related]
32. Identification and Validation of a Tumor Microenvironment-Related Gene Signature for Prognostic Prediction in Advanced-Stage Non-Small-Cell Lung Cancer.
Zhang X; Shi X; Zhao H; Jia X; Yang Y
Biomed Res Int; 2021; 2021():8864436. PubMed ID: 33860055
[TBL] [Abstract][Full Text] [Related]
33. A 16-mRNA signature optimizes recurrence-free survival prediction of Stages II and III gastric cancer.
Peng K; Chen E; Li W; Cheng X; Yu Y; Cui Y; Li Q; Wang Y; Xu X; Tang C; Gan L; Yu S; Liu T
J Cell Physiol; 2020 Jul; 235(7-8):5777-5786. PubMed ID: 32048287
[TBL] [Abstract][Full Text] [Related]
34. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma.
Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K
World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911
[TBL] [Abstract][Full Text] [Related]
35. A methylomics-associated nomogram predicts the overall survival risk of stage III to IV ovarian cancer.
Wei X; Hu W; Mao K
Medicine (Baltimore); 2023 Feb; 102(5):e32766. PubMed ID: 36749233
[TBL] [Abstract][Full Text] [Related]
36. Calculating the overall survival probability in patients with cervical cancer: a nomogram and decision curve analysis-based study.
Xie G; Wang R; Shang L; Qi C; Yang L; Huang L; Yang W; Chung MC
BMC Cancer; 2020 Sep; 20(1):833. PubMed ID: 32873257
[TBL] [Abstract][Full Text] [Related]
37. Immune Landscape of Gastric Carcinoma Tumor Microenvironment Identifies a Peritoneal Relapse Relevant Immune Signature.
Zhang C; Li D; Yu R; Li C; Song Y; Chen X; Fan Y; Liu Y; Qu X
Front Immunol; 2021; 12():651033. PubMed ID: 34054812
[TBL] [Abstract][Full Text] [Related]
38. Development and validation of nomograms for predicting survival of elderly patients with stage I small-cell lung cancer.
Yang Y; Sun S; Wang Y; Xiong F; Xiao Y; Huang J
Bosn J Basic Med Sci; 2021 Oct; 21(5):632-641. PubMed ID: 33577444
[TBL] [Abstract][Full Text] [Related]
39. Development and validation of an immune gene-set based prognostic signature for soft tissue sarcoma.
Shen R; Liu B; Li X; Yu T; Xu K; Ma J
BMC Cancer; 2021 Feb; 21(1):144. PubMed ID: 33557781
[TBL] [Abstract][Full Text] [Related]
40. Development and validation of epithelial mesenchymal transition-related prognostic model for hepatocellular carcinoma.
Wang X; Xing Z; Xu H; Yang H; Xing T
Aging (Albany NY); 2021 Apr; 13(10):13822-13845. PubMed ID: 33929972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
